Jack A. Khattar - 14 Mar 2022 Form 4/A - Amendment Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: President, CEO, Director
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol: SUPN
Transactions as of: 14 Mar 2022
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 13 Jan 2023, 16:00:58 UTC
Date Of Original Report: 17 Mar 2022
Previous filing: 24 Feb 2022
Next filing: 23 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Options Exercise	$0	+40,000	+7.7%	$0.000000	556,466	14 Mar 2022	Direct	F1
transaction	SUPN	Common Stock	Award	$0	+20,000	+3.6%	$0.000000	576,466	14 Mar 2022	Direct	F1
holding	SUPN	Common Stock						1,058,450	14 Mar 2022	By the KBT Trust
holding	SUPN	Common Stock						4,000	14 Mar 2022	By Son	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Performance Share Unit	Options Exercise	$0	-40,000	-100%	$0.000000^*	0	14 Mar 2022	Common Stock	40,000	$0.000000	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 19, 2021.
F2	The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.
F3	On February 19, 2021, the Reporting Person was awarded Performance Shares Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period.